AR084337A1 - Azaindoles como agentes antivirales del virus respiratorio sincicial - Google Patents

Azaindoles como agentes antivirales del virus respiratorio sincicial

Info

Publication number
AR084337A1
AR084337A1 ARP110104742A ARP110104742A AR084337A1 AR 084337 A1 AR084337 A1 AR 084337A1 AR P110104742 A ARP110104742 A AR P110104742A AR P110104742 A ARP110104742 A AR P110104742A AR 084337 A1 AR084337 A1 AR 084337A1
Authority
AR
Argentina
Prior art keywords
alkyl
group
cycloalkyl
alkoxy
halogen
Prior art date
Application number
ARP110104742A
Other languages
English (en)
Original Assignee
Janssen R & D Ireland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen R & D Ireland filed Critical Janssen R & D Ireland
Publication of AR084337A1 publication Critical patent/AR084337A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Azaindoles que tiene actividad inhibitoria sobre la replicación de VRS y composiciones que contienen estos compuestos como ingrediente activo y procesos para preparar estos componentes y composiciones.Reivindicación 1: Un compuesto que satisface la fórmula (1), un profármaco, un N-óxido, una sal por adición, una amina cuaternaria, un complejo metálico, o una de sus formas estereoquímicamente isoméricas; donde cada X independientemente es C o N con al menos un X que es N; R1 está presente cuando X = C y R1 se selecciona del grupo de H, OH, halógeno, alquilo C1-6, cicloalquilo C3-7, alcoxi C1-6, N(R6)2, CO(R7), CH2NH2, CH2OH, CN, C(=NOH)NH2, C(=NOCH3)NH2, C(=NH)NH2, CF3, OCF3, y B(OH)2; B(O-alquil C1-6)2; R2 se selecciona del grupo que consiste en H, halógeno, alquilo C1-6, cicloalquilo C3-7, alcoxi C1-6, y CO(R7); R3 es -(CR8R9)n-R10; R4 se selecciona del grupo que consiste en H, alquilo C1-10, CH2CF3 cicloalquilo C3-7, alquenilo C2-10, SO2-R8, o un anillo saturado de 4 a 6 miembros que contiene un átomo de oxígeno; R5 está presente cuando Y es C, y se selecciona del grupo que consiste en H, alquilo C1-6, cicloalquilo C3-7, alcoxi C1-6, CO(R7), CF3 y halógeno; R5 está ausente cuando X es N; R6 se selecciona del grupo que consiste en H, alquilo C1-6, COOCH3, y CONHSO2CH3; R7 se selecciona del grupo que consiste en OH, O(alquilo C1-6), NH2, NHSO2N(alquilo C1-6)2, NHSO2NHCH3, NHSO2(alquilo C1-6), NHSO2(cicloalquilo C3-7), y N(alquilo C1-6)2; n es un número entero de 2 a 6; R8 y R9 se seleccionan independientemente entre H, alquilo C1-10, cicloalquilo C3-7 o R8 y R9 tomados en conjunto forman un anillo alifático de 4 a 6 miembros que opcionalmente contiene un heteroátomo seleccionado del grupo N, S, O; R10 se selecciona del grupo que consiste en H, alquilo C1-6, OH, CN, F, CF2H, CF3, CONR8R9, COOR8, CONR8SO2R9, CON(R8)SO2N(R8R9), NR8R9, NR8COOR9, OCOR8, NR8SO2R9, SO2NR8R9, SO2R8 o un anillo saturado de 4 a 6 miembros que contiene un átomo de oxígeno.
ARP110104742A 2010-12-16 2011-12-16 Azaindoles como agentes antivirales del virus respiratorio sincicial AR084337A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10195473 2010-12-16

Publications (1)

Publication Number Publication Date
AR084337A1 true AR084337A1 (es) 2013-05-08

Family

ID=43920170

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104742A AR084337A1 (es) 2010-12-16 2011-12-16 Azaindoles como agentes antivirales del virus respiratorio sincicial

Country Status (12)

Country Link
US (3) US9051317B2 (es)
EP (1) EP2651936B1 (es)
JP (1) JP5876502B2 (es)
KR (1) KR101876791B1 (es)
CN (1) CN103339128B (es)
AR (1) AR084337A1 (es)
AU (1) AU2011343259B2 (es)
CA (1) CA2822002C (es)
EA (1) EA025402B1 (es)
ES (1) ES2624263T3 (es)
TW (1) TWI501967B (es)
WO (1) WO2012080450A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI541241B (zh) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI530495B (zh) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
AU2013276519B2 (en) 2012-06-15 2017-05-25 Janssen Sciences Ireland Uc 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
US20150158862A1 (en) * 2012-06-15 2015-06-11 Janssen R&D Ireland 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
MX363717B (es) 2012-10-16 2019-03-29 Janssen Sciences Ireland Uc Compuestos antiviricos para el virus sincitial respiratorio.
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
RU2015148926A (ru) 2013-05-14 2017-06-15 Ф. Хоффманн-Ля Рош Аг Аза-оксо-индолы для лечения и профилактики респираторно-синцитиальной вирусной инфекции
CN105392787B (zh) * 2013-05-14 2017-11-24 豪夫迈·罗氏有限公司 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚
CN105408330A (zh) * 2013-08-12 2016-03-16 豪夫迈·罗氏有限公司 新的用于治疗和预防呼吸道合胞病毒感染的氮杂-氧代-吲哚
CA2914529A1 (en) * 2013-08-12 2015-02-19 F. Hoffmann-La Roche Ag Novel aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
BR112016003348B1 (pt) 2013-08-21 2023-03-07 Alios Biopharma, Inc Compostos antivirais ou sais farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e seus usos
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為rsv抗病毒化合物之螺脲化合物
US20160045528A1 (en) * 2014-08-05 2016-02-18 Alios Biopharma, Inc. Combination therapy for treating a paramyxovirus
MA41614A (fr) 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
MX2018000916A (es) 2015-07-22 2018-09-05 Enanta Pharm Inc Derivados de benzodiazepina como inhibidores de rsv.
BR112018010216B1 (pt) 2015-11-20 2024-02-15 Forma Therapeutics, Inc Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos
US20170226129A1 (en) 2016-01-15 2017-08-10 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as rsv inhibitors
US9781457B1 (en) 2016-03-31 2017-10-03 Google Inc. Methods, systems, and media for indicating viewership of a video based on context
EP3582784B1 (en) 2017-02-16 2022-06-08 Enanta Pharmaceuticals, Inc. Processes for the preparation of benzodiazepine derivatives
US11091501B2 (en) 2017-06-30 2021-08-17 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
WO2019067864A1 (en) 2017-09-29 2019-04-04 Enanta Pharmaceuticals, Inc. PHARMACEUTICAL AGENTS IN COMBINATION AS INHIBITORS OF RSV
AU2018365174B2 (en) 2017-11-13 2023-03-30 Enanta Pharmaceuticals, Inc. Processes for the resolution of benzodiazepin-2-one and benzoazepin-2-one derivatives
EP3897670A4 (en) 2018-12-19 2022-09-07 Disarm Therapeutics, Inc. MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS
US11254664B2 (en) 2019-03-18 2022-02-22 Enanta Pharmaceuticals, Inc. Benzodiazepine derivatives as RSV inhibitors
KR20220101083A (ko) 2019-10-04 2022-07-19 이난타 파마슈티칼스, 인코포레이티드 항바이러스 헤테로사이클릭 화합물
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
US12064421B2 (en) 2020-11-02 2024-08-20 Boehringer Ingelheim International Gmbh Substituted 1H-pyrazolo[4,3-c]pyridines and derivatives as EGFR inhibitors
JP2024507561A (ja) 2021-02-26 2024-02-20 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス複素環式化合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002514162A (ja) 1996-07-08 2002-05-14 デュポン ファーマシューティカルズ カンパニー Xa因子阻害薬およびトロンビン阻害薬としてのアミジノインドール類、アミジノアゾール類、およびそれらの類似体
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
US6867200B1 (en) * 1998-12-18 2005-03-15 Axys Pharmaceuticals, Inc. (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
OA11978A (en) * 1999-06-28 2006-04-18 Janssen Pharmaceutica Nv Respiratory syncytial virus replication inhibitors.
PT1196409E (pt) * 1999-06-28 2004-06-30 Janssen Pharmaceutica Nv Inibidores da replicacao do virus sincicial respiratorio
AU6762400A (en) * 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
NL1013900C2 (nl) 1999-12-21 2001-06-25 Akzo Nobel Nv Werkwijze voor de vervaardiging van een zonnecelfolie met in serie geschakelde zonnecellen.
AU2001236605A1 (en) 2000-02-01 2001-08-14 Cor Therapeutics, Inc. Indole and benzimidazole inhibitors of factor xa
WO2001057019A1 (en) 2000-02-01 2001-08-09 Cor Therapeutics, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
US6489338B2 (en) * 2000-06-13 2002-12-03 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrimidine antiviral agents
US6506738B1 (en) * 2000-09-27 2003-01-14 Bristol-Myers Squibb Company Benzimidazolone antiviral agents
US6919331B2 (en) 2001-12-10 2005-07-19 Bristol-Myers Squibb Company Substituted 2-methyl-benzimidazole respiratory syncytial virus antiviral agents
HUP0402535A2 (hu) 2001-12-10 2005-04-28 Bristol-Myers Squibb Co. RSV fúzió inhibitor hatású imidazo-piridin-vegyület dihidroklorid-monohidrát sója és az ezt tartalmazó gyógyszerkészítmények
WO2003056344A2 (en) 2001-12-21 2003-07-10 Sense Proteomic Limited Protein analysis using mass spectrometry
AU2003294249A1 (en) * 2002-11-08 2004-06-03 Trimeris, Inc. Hetero-substituted benzimidazole compounds and antiviral uses thereof
PE20050068A1 (es) * 2003-02-06 2005-03-11 Novartis Ag 2-cianopirrolopirimidinas como inhibidores de la catepsina s
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
FR2911605B1 (fr) * 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de pyrrolopyridine-2-carbowamides, leur preparation et leur application en therapeutique
JP5268120B2 (ja) 2007-05-22 2013-08-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンゾイミダゾロンキマーゼ阻害薬
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
TWI530495B (zh) * 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 苯并咪唑呼吸道融合病毒抑制劑
TWI515187B (zh) * 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI527814B (zh) * 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI501967B (zh) 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
TWI541241B (zh) * 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之咪唑并吡啶類
CA2821367A1 (en) 2010-12-17 2012-06-21 Sanofi-Aventis Deutschland Gmbh Medicament administration
EA201590020A1 (ru) * 2012-06-15 2015-03-31 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса
US20150158862A1 (en) * 2012-06-15 2015-06-11 Janssen R&D Ireland 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
KR20150028969A (ko) * 2012-06-15 2015-03-17 얀센 알 앤드 디 아일랜드 호흡기 합포체 바이러스의 항바이러스제로서의 벤즈이미다졸로 치환된 4-치환된 1,3-디하이드로-2h-벤즈이미다졸-2-온 유도체
AU2013276519B2 (en) * 2012-06-15 2017-05-25 Janssen Sciences Ireland Uc 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
MX363717B (es) * 2012-10-16 2019-03-29 Janssen Sciences Ireland Uc Compuestos antiviricos para el virus sincitial respiratorio.

Also Published As

Publication number Publication date
US20130267556A1 (en) 2013-10-10
US9339494B2 (en) 2016-05-17
EP2651936A1 (en) 2013-10-23
JP2013545787A (ja) 2013-12-26
KR20140014093A (ko) 2014-02-05
ES2624263T3 (es) 2017-07-13
CA2822002A1 (en) 2012-06-21
EP2651936B1 (en) 2017-02-22
US9051317B2 (en) 2015-06-09
EA025402B1 (ru) 2016-12-30
CA2822002C (en) 2019-08-06
US20160251377A1 (en) 2016-09-01
CN103339128A (zh) 2013-10-02
TWI501967B (zh) 2015-10-01
EA201390885A1 (ru) 2013-09-30
KR101876791B1 (ko) 2018-08-09
AU2011343259B2 (en) 2014-11-27
AU2011343259A1 (en) 2013-05-02
CN103339128B (zh) 2015-11-25
TW201305158A (zh) 2013-02-01
WO2012080450A1 (en) 2012-06-21
JP5876502B2 (ja) 2016-03-02
US20150231119A1 (en) 2015-08-20
US9896459B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
AR084337A1 (es) Azaindoles como agentes antivirales del virus respiratorio sincicial
AR084338A1 (es) Imidazopiridinas como agentes antivirales del virus sincicial respiratorio
AR084336A1 (es) Azabencimidazoles como agentes antivirales del virus sincicial respiratorio
AR084335A1 (es) Derivados indolicos de imidazo[4,5-c]piridina, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos como agentes antivirales para el virus sincitial respiratorio (rsv)
BR112015015216A2 (pt) composto de tetrazolinona e uso do mesmo
AR062680A1 (es) Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas
AR080328A1 (es) Tienopirimidinas que contienen un grupo alquilo sustituido inhibidoras de quinasas mnk1 y/o mnk2, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de trastornos metabolicos tales como diabetes y obesidad, y trastornos hiperproliferativos, entre otros
AR091023A1 (es) Inhibidores del nampt
TR201911151T4 (tr) Jak2 ve alk2 inhibitörleri ve bunların kullanım yöntemleri.
AR091455A1 (es) Derivados 1,3-dihidro-2h-benzimidazol-2-ona sustituidos con heterociclos como agentes antivirales para el virus sincicial respiratorio
BR112015004529A2 (pt) alcóxi pirazóis como ativadores de guanilato ciclase solúvel
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
AR065772A1 (es) Compuestos de indolobenzazepina para el tratamiento de la hepatitis c. composiciones farmaceuticas.
AR085203A1 (es) Inhibidores benzimidazol del virus sincitial respiratorio
MX2016001788A (es) Derivados de benzimidazolil-metil urea como agonistas del receptor de alx.
MX2016007566A (es) Derivados de amina ciclica de fenoxietilo y su actividad como moduladores de receptor ep4.
MX2015001099A (es) Nuevos derivados biciclicos de piridina.
MX343225B (es) Nuevos derivados de aril-benzocicloalquil-amida.
BR112014019344A8 (pt) Solução aquosa que absorve eficientemente erecupera dióxido de carbono no gás de exaustão e método para recuperar o dióxido de carbono usando a mesma
MX347855B (es) Derivados de anilina, su preparación y su aplicación terapéutica.
PE20151155A1 (es) Derivados de carbamato/urea
PH12014502285A1 (en) Anti-malarial agents
MX2015016400A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX2015015010A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
MX2015000163A (es) Nuevos indazoles para el tratamiento y la profilaxis de la infeccion por virus sincitial respiratorio.

Legal Events

Date Code Title Description
FB Suspension of granting procedure